Zugänglichkeit
Animation
Zugänglichkeit

nAbCyte™ CDx: One-time treatment. Zero room for error.

3 October 2024

Break through in partnership

An estimated 6,000 people  in the United States live with hemophilia B. nAbCyte™—the first CDx for a cell-based gene therapy—offers new hope in delivering the right treatment to the right patients.


Explore our gene therapy and companion diagnostic services

Press release 

FDA approved the first companion diagnostic for use with Pfizer's newly approved gene therapy to treat patients with hemophilia B.

nAbCyte testing program

The nAbCyte Hemophilia B Testing Program helps determine patient eligibility for treatment with Pfizer’s hemophilia B gene therapy.

Cell and gene therapy 

From research and development of cell and gene therapy products to next-generation sequencing testing, you need answers—our scientists are here to help.

Companion diagnostics 

Parallel development of a companion diagnostic with a novel therapeutic is challenging—but the value of proving your treatment’s efficacy with targeted biomarkers has never been greater.